Over the past 12 months, 6 insiders at Bicara Therapeutics Inc. filed 69 open-market SEC Form 4 transactions on BCAX: 1 purchase worth $4.8M and 68 sales worth $12.2M. Insiders have been net sellers over this period. The most recent filing was on Jul 10, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 10, 26 | Claire MazumdarChief Executive Officer | SELL | 10.0K | $29.68 | $283K |
| Jul 9, 26 | Ryan CohlheppPresident and COO | SELL | 536 | $29.00 | $16K |
| Jul 8, 26 | Ryan CohlheppPresident and COO | SELL | 22.8K | $30.35 | $657K |
| Jul 8, 26 | Ivan HyepChief Financial Officer | SELL | 22.8K | $30.31 | $651K |
| May 21, 26 | Ivan HyepChief Financial Officer | SELL | 9.2K | $20.42 | $188K |
| May 18, 26 | Claire MazumdarChief Executive Officer | SELL | 12.0K | $20.35 | $240K |
| May 15, 26 | Ryan CohlheppPresident and COO | SELL | 8.0K | $20.29 | $162K |
| Apr 27, 26 | David RabenChief Medical Officer | SELL | 5.5K | $22.88 | $126K |
| Apr 21, 26 | Ivan HyepChief Financial Officer | SELL | 9.2K | $23.00 | $212K |
| Apr 20, 26 | Claire MazumdarChief Executive Officer | SELL | 15.0K | $23.61 | $354K |
| Apr 15, 26 | Ryan CohlheppPresident and COO | SELL | 8.0K | $23.01 | $184K |
| Mar 25, 26 | David RabenChief Medical Officer | SELL | 5.5K | $18.95 | $104K |
| Mar 23, 26 | Ivan HyepChief Financial Officer | SELL | 9.2K | $18.52 | $170K |
| Mar 20, 26 | Claire MazumdarChief Executive Officer | SELL | 1.6K | $18.95 | $30K |
| Mar 19, 26 | Claire MazumdarChief Executive Officer | SELL | 6.9K | $18.78 | $130K |
| Mar 18, 26 | Claire MazumdarChief Executive Officer | SELL | 6.5K | $18.84 | $122K |
| Mar 16, 26 | Ryan CohlheppPresident and COO | SELL | 8.0K | $19.66 | $157K |
| Mar 9, 26 | Claire MazumdarChief Executive Officer | SELL | 36.8K | $19.17 | $705K |
| Mar 6, 26 | Claire MazumdarChief Executive Officer | SELL | 3.8K | $18.75 | $72K |
| Mar 5, 26 | Claire MazumdarChief Executive Officer | SELL | 1.8K | $18.74 | $33K |
| Mar 4, 26 | Claire MazumdarChief Executive Officer | SELL | 2.6K | $18.73 | $49K |
| Mar 4, 26 | Ivan HyepChief Financial Officer | SELL | 3.0K | $18.25 | $54K |
| Mar 4, 26 | David RabenChief Medical Officer | SELL | 16.3K | $18.52 | $302K |
| Mar 3, 26 | Ryan CohlheppPresident and COO | SELL | 12.9K | $18.16 | $234K |
| Mar 3, 26 | Ivan HyepChief Financial Officer | SELL | 13.6K | $18.22 | $247K |
| Mar 3, 26 | David RabenChief Medical Officer | SELL | 200 | $18.45 | $4K |
| Feb 26, 26 | Ra Capital Management, L.p.Director,TenPercentOwner | BUY | 300.0K | $16.00 | $4.8M |
| Feb 25, 26 | Ryan CohlheppPresident and COO | SELL | 3.1K | $18.04 | $56K |
| Jan 22, 26 | Ryan CohlheppPresident and COO | SELL | 3.8K | $18.10 | $69K |
| Jan 22, 26 | Ivan HyepChief Financial Officer | SELL | 1.9K | $18.15 | $34K |
| Jan 15, 26 | Ryan CohlheppPresident and COO | SELL | 149 | $18.02 | $3K |
| Dec 22, 25 | Ivan HyepChief Financial Officer | SELL | 9.2K | $18.31 | $168K |
| Dec 15, 25 | Ryan CohlheppPresident and COO | SELL | 8.0K | $18.68 | $149K |
| Nov 25, 25 | David RabenChief Medical Officer | SELL | 4.6K | $18.84 | $87K |
| Nov 24, 25 | Claire MazumdarChief Executive Officer | SELL | 41.2K | $18.86 | $776K |
| Nov 24, 25 | David RabenChief Medical Officer | SELL | 5.5K | $18.45 | $101K |
| Nov 24, 25 | Ivan HyepChief Financial Officer | SELL | 17.8K | $18.55 | $330K |
| Nov 21, 25 | Ryan CohlheppPresident and COO | SELL | 8.0K | $18.05 | $144K |
| Nov 21, 25 | Ivan HyepChief Financial Officer | SELL | 605 | $18.15 | $11K |
| Oct 16, 25 | Claire MazumdarChief Executive Officer | SELL | 24.1K | $18.83 | $454K |
| Oct 15, 25 | Ryan CohlheppPresident and COO | SELL | 8.0K | $18.16 | $145K |
| Oct 15, 25 | Claire MazumdarChief Executive Officer | SELL | 13.3K | $18.84 | $250K |
| Oct 13, 25 | Claire MazumdarChief Executive Officer | SELL | 11.4K | $18.92 | $217K |
| Oct 9, 25 | Ivan HyepChief Financial Officer | SELL | 6.4K | $18.23 | $117K |
| Oct 9, 25 | David RabenChief Medical Officer | SELL | 22.0K | $18.45 | $406K |
| Oct 8, 25 | Ivan HyepChief Financial Officer | SELL | 5.6K | $18.21 | $102K |
| Oct 7, 25 | Ryan CohlheppPresident and COO | SELL | 8.0K | $18.06 | $144K |
| Oct 7, 25 | Ivan HyepChief Financial Officer | SELL | 18.2K | $18.22 | $332K |
| Oct 6, 25 | Ryan CohlheppPresident and COO | SELL | 24.0K | $18.06 | $433K |
| Oct 6, 25 | Ivan HyepChief Financial Officer | SELL | 6.5K | $18.17 | $118K |
Over the past 12 months, insiders at Bicara Therapeutics Inc. filed 1 open-market purchase worth $4.8M and 68 sales worth $12.2M on BCAX, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 10, 26.
The largest recent open-market BCAX insider purchase in our data was $4.8M by Ra Capital Management, L.p., Director,TenPercentOwner, filed on Feb 26, 26.
6 different insiders at Bicara Therapeutics Inc. filed open-market SEC Form 4 transactions on BCAX over the last 12 months.
InsiderTape plots every BCAX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Bicara Therapeutics Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →